U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula 2C14H13ClF6N6.C6H8O7
Molecular Weight 1021.597
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VORASIDENIB CITRATE ANHYDROUS

SMILES

OC(=O)CC(O)(CC(O)=O)C(O)=O.C[C@@H](NC1=NC(=NC(N[C@H](C)C(F)(F)F)=N1)C2=CC=CC(Cl)=N2)C(F)(F)F.C[C@@H](NC3=NC(=NC(N[C@H](C)C(F)(F)F)=N3)C4=CC=CC(Cl)=N4)C(F)(F)F

InChI

InChIKey=OCEHQNOYRLHJCI-WPRTUUMNSA-N
InChI=1S/2C14H13ClF6N6.C6H8O7/c2*1-6(13(16,17)18)22-11-25-10(8-4-3-5-9(15)24-8)26-12(27-11)23-7(2)14(19,20)21;7-3(8)1-6(13,5(11)12)2-4(9)10/h2*3-7H,1-2H3,(H2,22,23,25,26,27);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/t2*6-,7-;/m11./s1

HIDE SMILES / InChI

Molecular Formula C6H8O7
Molecular Weight 192.1235
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C14H13ClF6N6
Molecular Weight 414.737
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Vorasidenib (also known as AG 881) was developed as an isocitrate dehydrogenase (IDH) type 1 in the cytoplasm and type 2 in the mitochondria, with potential antineoplastic activity. It is known that IDH is an essential enzyme for cellular respiration in the tricarboxylic acid (TCA) cycle. Isocitrate dehydrogenases 1 and 2 (IDH1/2) are homodimeric enzymes that catalyze the conversion of isocitrate to α-ketoglutarate (α-KG) in the tricarboxylic acid cycle. Vorasidenib participated in phase I clinical trials in patients with advanced hematologic malignancies and in gliomas.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P48735
Gene ID: 3418.0
Gene Symbol: IDH2
Target Organism: Homo sapiens (Human)
Target ID: O75874
Gene ID: 3417.0
Gene Symbol: IDH1
Target Organism: Homo sapiens (Human)
PubMed

PubMed

TitleDatePubMed
The Evolving Landscape in the Development of Isocitrate Dehydrogenase Mutant Inhibitors.
2016
Targeting isocitrate dehydrogenase (IDH) in cancer.
2016 May
Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective.
2018 Oct 25
Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2.
2018 Sep 18

Sample Use Guides

oral doses of AG-881 to determine maximum tolerated dose (MTD) and/or the recommended Phase II dose
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Dec 16 15:38:53 UTC 2023
Edited
by admin
on Sat Dec 16 15:38:53 UTC 2023
Record UNII
W4XG3EQK7B
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
VORASIDENIB CITRATE ANHYDROUS
Common Name English
AG-881 HEMICITRATE
Code English
VORASIDENIB HEMICITRATE
Common Name English
1,3,5-TRIAZINE-2,4-DIAMINE, 6-(6-CHLORO-2-PYRIDINYL)-N2,N4-BIS((1R)-2,2,2-TRIFLUORO-1-METHYLETHYL)-, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE (2:1)
Systematic Name English
Code System Code Type Description
CAS
2316810-00-9
Created by admin on Sat Dec 16 15:38:53 UTC 2023 , Edited by admin on Sat Dec 16 15:38:53 UTC 2023
PRIMARY
PUBCHEM
146675102
Created by admin on Sat Dec 16 15:38:53 UTC 2023 , Edited by admin on Sat Dec 16 15:38:53 UTC 2023
PRIMARY
SMS_ID
300000028875
Created by admin on Sat Dec 16 15:38:53 UTC 2023 , Edited by admin on Sat Dec 16 15:38:53 UTC 2023
PRIMARY
FDA UNII
W4XG3EQK7B
Created by admin on Sat Dec 16 15:38:53 UTC 2023 , Edited by admin on Sat Dec 16 15:38:53 UTC 2023
PRIMARY
Related Record Type Details
SOLVATE->ANHYDROUS
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY